Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207231 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 837
- Enrollment target
NCT02207231 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 837 participants.
The verdict
NCT02207231, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 837 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
Interventions
- DRUG Adalimumab
- DRUG Placebo for guselkumab
- DRUG Placebo for adalimumab
- DRUG Guselkumab 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 837 participants |
| Start Date | 2014-11-26 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207231
The ClinicalTrials.gov registry entry for NCT02207231 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 837 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT02207231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207231 about?
NCT02207231 is a clinical study titled "A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
What is the current status of trial NCT02207231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 837 participants. The study started on 2014-11-26. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT02207231?
The interventions under investigation include: Adalimumab (DRUG), Placebo for guselkumab (DRUG), Placebo for adalimumab (DRUG), Guselkumab 100 mg (DRUG).
Who is sponsoring clinical trial NCT02207231?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.